Article citationsMore >>

diCapua Siegel DS, Jacobus S, Rajkumar SV, Abonour R, Callander NS, Katz MS, Fonseca R, Vesole DH. “Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial (Abstract 38),” Blood (ASH Annual Meeting Abstracts), 116 38, 2010.

has been cited by the following article:

Article

Is There Still a Role for High-Dose Melphalan and Stem Cell Transplantation in the Treatment of Multiple Myeloma?

1Department of Medicine, College of Medicine, Mayo Distinguished Clinician, Rochester


International Journal of Hematological Disorders. 2014, Vol. 1 No. 1A, 7-12
DOI: 10.12691/ijhd-1-1A-2
Copyright © 2014 Science and Education Publishing

Cite this paper:
Morie A. Gertz, Francis K. Buadi, Martha Q. Lacy. Is There Still a Role for High-Dose Melphalan and Stem Cell Transplantation in the Treatment of Multiple Myeloma?. International Journal of Hematological Disorders. 2014; 1(1A):7-12. doi: 10.12691/ijhd-1-1A-2.

Correspondence to: Morie  A. Gertz, Department of Medicine, College of Medicine, Mayo Distinguished Clinician, Rochester. Email: gertz.morie@mayo.edu

Abstract

Stem cell transplantation was demonstrated to have a survival value in the era prior to the introduction of novel agents for the treatment of multiple myeloma. It has become reasonable to begin to question the value of stem cell transplantation. In this review, we analyzed available data and ongoing trials to determine whether or not the evidence is sufficient to continue using stem cell transplantation as a primary modality for the treatment of the eligible patient with multiple myeloma.

Keywords